Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Pharmasset, Inc. Company Profile

15:21 EDT 24th July 2014 | BioPortfolio

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of human immunodeficiency virus, or HIV, hepatitis B virus, or HBV, and hepatitis C virus, or HCV. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication.


303-A College Road East
New Jersey
United States of America


Phone: (609) 613-4100
Fax: (609) 613-4150

News Articles [8 Associated News Articles listed on BioPortfolio]

Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms

ByAustrolib:Merck's (MRK) acquisition of Idenix (IDIX) for its hepatitis C [HCV] platform has certainly created a storm of chatter in the investment community. 12 articles have been published on Seeki...

Comment on Bringing New Rx Drugs to Market in 2014 by Mike Wokasch

I think it is important to also point out that it cost Gilead $11 billion to acquire Pharmasset and thereby secure the rights to Sovaldi. They still had to pay costs associated with completing develo...

Senators push for details on Sovaldi's cost

Two members of the Senate Finance Committee requested pricing information for HCV drug Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), including an explanation of the difference between th...

Gilead's Potential Riches Spawns Hepatitis Wars

Gilead's hepatitis C drug, Solvaldi, sales have really taken off. Analysts are predicting megablockbuster status -- with high predictions of as much as $8 B in annual sales by as early as this year. T...

Senate Finance Committee Probing Prices For Hepatitis C Drug

Sens. Ron Wyden, D-Ore., and Charles Grassley, R-Iowa, send letter to the drug's maker requesting information about how it set the price, which runs about $84,000 for a standard three-month regimen. T...

Sovaldi's Q1 Is A Home Run With Men On Base; Why Gilead May Triple From Here

ByDoctoRx:Background: I have written twice about Gilead Sciences (GILD). A few weeks ago I wrote A Physician-Businessman's Views Of Gilead, With Emphasis On Sovaldi, and after the stock price and othe...

Why Gilead Sciences Is Heading To $80

By Wall Street Playbook:The healthcare industry is highly competitive. Nowhere else does the term "survival of the fittest" proves true. In this sector, companies survive by maintaining strong drug pi...

Gilead Sciences: Strong Long-Term Growth At A Bargain

ByGaurav S. Sharma:Gilead Sciences (GILD) has been a tremendous performer over the last few years as part of the multi-year biotech bull market. However, it has taken a significant dip in the past few...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

Pharmasset, Inc.

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeut...

More Information about "Pharmasset, Inc." on BioPortfolio

We have published hundreds of Pharmasset, Inc. news stories on BioPortfolio along with dozens of Pharmasset, Inc. Clinical Trials and PubMed Articles about Pharmasset, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmasset, Inc. Companies in our database. You can also find out about relevant Pharmasset, Inc. Drugs and Medications on this site too.

Search BioPortfolio:

Relevant Topics

AIDS and HIV · Latest News · Clinical Trials · Research · Drugs · Reports · Corporate
AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for HIV in patients. People who have the HIV antibodies are...

The top 5 most promising drugs (February 2014) · Latest News · Clinical Trials · Research · Drugs · Reports · Corporate
THE FIVE MOST PROMISING DRUGS LAUNCHED OR RECEIVING APPROVAL February 2014 Drug Disease Company Gazyva™ Chronic lymphocytic leukemia Biogen Idec/Genentech/ F. Hoffman-La Roche...

Gastroenterology · Latest News · Clinical Trials · Research · Drugs · Reports · Corporate
Diseases affecting the gastrointestinal tract, which includes the organs from mouth to anus, along the alimentary canal, are the focus of this specialty. Physicians practicing in this field of medicine are called gastroenterologists.  Gastroenterolo...


Corporate Database Quicklinks

Searches Linking to this Company Record